$VNDA Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.37 up 2.63% YoY
• Reported revenue of $1.61M down -97.14% YoY
• Vanda Pharmaceuticals expects full-year 2026 total revenue of greater than $240M; no quantified margin or earnings guidance was provided for full-year 2026 in the financial update.